(Q54312158)

English

Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.

scientific article published on 31 October 2014

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

author name string

I Treilleux

1

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

M Arnedos

2

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

C Cropet

3

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

Q Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

J-M Ferrero

5

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

S Abadie-Lacourtoisie

6

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

C Levy

7

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

E Legouffe

8

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

A Lortholary

9

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

E Pujade-Lauraine

10

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

A-V Bourcier

11

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

J-C Eymard

12

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

D Spaeth

13

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

T Bachelot

14

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

publication date

31 October 2014

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

26

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

1

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

120-125

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

Biological determinants of endocrine resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

Akt-dependent and -independent mechanisms of mTOR regulation in cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

TOR signaling in growth and metabolism

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

Comprehensive molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

TSC2 mediates cellular energy response to control cell growth and survival

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

Elevated PI3K signaling drives multiple breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

PIK3CA mutation associates with improved outcome in breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

Phosphoprotein stability in clinical tissue and its relevance for reverse phase protein microarray technology

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

Activation of rapid oestrogen signalling in aggressive human breast cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibit

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU497

21 January 2018

Identifiers

10.1093/ANNONC/MDU497

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

release_yeqoiownevabtipmg6f2c3nbiu

1 reference

https://api.fatcat.wiki/v0/release/yeqoiownevabtipmg6f2c3nbiu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25361980

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54312158&oldid=1837786583"